<--- Back to Details
First PageDocument Content
Microbiology / IPrEx / Gilead Sciences / Sexually transmitted diseases and infections / Microbicides / Pre-exposure prophylaxis / HIV prevention / Tenofovir/emtricitabine / Antiretroviral drug / HIV/AIDS / Medicine / Health
Date: 2011-01-04 17:29:31
Microbiology
IPrEx
Gilead Sciences
Sexually transmitted diseases and infections
Microbicides
Pre-exposure prophylaxis
HIV prevention
Tenofovir/emtricitabine
Antiretroviral drug
HIV/AIDS
Medicine
Health

Microsoft PowerPoint - iPrEx1-11revised [Compatibility Mode] [Read-Only]

Add to Reading List

Source URL: www.publichealth.lacounty.gov

Download Document from Source Website

File Size: 179,70 KB

Share Document on Facebook

Similar Documents

An analysis of baseline data from the PROUD study: an open-label randomised trial of pre-exposure prophylaxis

DocID: 1ut18 - View Document

Pragmatic Open-Label Randomised Trial of Pre-Exposure Prophylaxis: the PROUD study http://www.proud.mrc.ac.uk/

DocID: 1uc90 - View Document

A publication for men and transgender women who have sex with men Pre-exposure Prophylaxis Is taking PrEP the

DocID: 1u249 - View Document

Final Draft – 11 MayGuidelines for Expanding Combination Prevention and Treatment Options for Sex Workers: Oral Pre-Exposure Prophylaxis (PrEP) and Test and Treat (T&T)

DocID: 1t04u - View Document

Pre-Exposure Prophylaxis (PrEP): A primer for primary care providers Daily emtricitabine/tenofovir (Truvada®) is safe and effective for reducing the risk of HIV acquisition in sexually active men and women and injection

DocID: 1rPaA - View Document